CNTA Centessa Pharmaceuticals plc

Overview and Growth

Fiscal 2025 results for Centessa Pharmaceuticals plc combined $15.00M of revenue with net loss of $197.53M and an operating cash outflow of $193.82M. The $15.00M revenue base provides substantial context for the company’s earnings, cash generation, and capital requirements. Diluted earnings per share were -$1.46, translating the period’s attributable earnings into the amount reported for each diluted share. The diluted weighted-average share count was 135.72M, linking total earnings with the per-share result received by shareholders. Compared with 114.47M diluted shares in fiscal 2024, the current 135.72M base was 18.6% higher. At period end, total assets were $687.50M, framing the scale of the company’s operating and financing commitments. Revenue equaled 0.02x of total assets, indicating how much reported top-line activity the company produced relative to its period-end asset base.

Profitability

Operations produced a $207.69M operating loss before non-operating and tax effects. The bottom-line result was a net loss of $197.53M after operating, financing, tax, and other recognized items. Negative EBITDA totaled $206.77M, confirming that the earnings deficit remained before depreciation and amortization. The pretax result was a loss of $195.71M, establishing the deficit before tax effects. The reported income-tax provision was $1.82M, the amount recognized between pretax income and the final net-income result. The net loss equaled 37.5% of period-end equity, showing the deficit relative to book capital. The net loss equaled 28.7% of period-end assets, showing the deficit relative to the asset base. Compared with a $235.76M net loss in fiscal 2024, the current loss improved to $197.53M.

Liquidity and Capital Structure

The company held $687.50M of assets against $160.63M of liabilities and $526.86M of equity, revealing how the asset base was financed. Current assets were $367.88M against $42.94M of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. At 8.57x, the current ratio shows that short-term assets were greater than short-term liabilities at period end. Reported cash and equivalents were $61.30M, separating immediately recognizable cash resources from the rest of the current-asset base. Cash and equivalents represented 142.8% of current liabilities, showing the portion of near-term obligations matched by reported cash alone. Total debt was $110.09M, establishing the amount of borrowing carried within the company’s capital structure. Debt equaled 0.21x of book equity, describing the relative scale of borrowing and shareholder capital. The debt-to-assets relationship was 16.0%, comparing borrowing with the total asset balance. Equity equaled 76.6% of assets, showing the shareholder-capital layer within the company’s balance sheet. Relative to total assets, liabilities measured 23.4%, complementing the separate equity-based view of the company’s capital structure. The cash-to-assets relationship was 8.9%, comparing reported cash and equivalents with the full positive asset balance. Compared with $576.80M in fiscal 2024, the current asset base moved 19.2% and finished higher. Against $401.55M of equity in fiscal 2024, the current book-equity balance moved 31.2% and ended higher. Compared with $383.22M in fiscal 2024, the current cash balance moved 84.0% and finished lower.

Cash Flow and Earnings Quality

Cash flow from operations was an outflow of $193.82M, showing that operations absorbed cash during the period. Capital spending of $371.00K added to the period’s operating cash use, reinforcing the overall cash deficit after investment for the year. Negative free cash flow was $194.19M, leaving a cash deficit after capital spending and reducing financial flexibility. Relative to total assets, the post-investment cash deficit measured 28.2%. The operating cash outflow widened to $193.82M from $142.06M in fiscal 2024.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Oct 21, 2026.